NCT02539511

Glutamatergic Modulation of Disordered Alcohol Use

The Effect of Brief Potent Glutamatergic Modulation on Disordered Alcohol Use

• Status: Completed
• Phase: Phase 2 / Phase 3
• Study type: Interventional
• Enrollment: 50 (actual)
• Sponsor: New York State Psychiatric Institute · Academic / Other
• Sex: All
• Age: 21 Years – 69 Years
• Healthy volunteers: Not accepted

Summary

Alcohol use disorders remain a significant public health problem. The pharmacological facilitation of behavioral treatment represents a promising strategy for addressing disordered drinking. Alcohol use disorders are recognized to be associated with various vulnerabilities that complicate the course of treatment and that may be amenable to glutamate modulators. The purpose of this randomized, double-blind, controlled trial is to test various glutamate modulators in conjunction with motivational enhancement therapy (MET) for alcohol use disorders.

Detailed description

Individuals diagnosed with alcohol dependence will be randomized to receive a single infusion of glutamate modulators during week 2 while engaged in a 5-week course of MET. They will meet with staff twice weekly, except for week 2 during which they will present to the clinic three times. Clinic visits include MET sessions, psychiatric monitoring, assessments, and study procedures (e.g., medication administration).

Conditions

• Alcohol Dependence

Interventions

Type	Name	Description
DRUG	CI-581a
DRUG	CI-581b
BEHAVIORAL	Motivational Enhancement Therapy (MET)

Timeline

• Start date: 2015-07-01
• Primary completion: 2017-09-01
• Completion: 2017-12-01
• First posted: 2015-09-03
• Last updated: 2020-02-11
• Results posted: 2019-04-23

Locations

1 site across 1 country: United States